Trial Profile
A prospective, exploratory, single-center clinical study for Anlotinib Hydrochloride combined with chemotherapy versus chemotherapy alone for advanced, recurrent, and persistent vaginal cancer, cervical cancer, and uterine malignancies
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Antineoplastics
- Indications Cervical cancer; Uterine diseases; Vulvovaginal cancer
- Focus Therapeutic Use
- 25 Jun 2019 New trial record